戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  obligations to guide future research in our commentary.
2 e etiologies are discussed in detail in this commentary.
3 omments on our target article made in the 25 commentaries.
4                       Here we respond to the commentaries.
5                                            A commentary [1] criticized our systematic review regardin
6 pirical studies, ethics documents and expert commentaries (2010 to present), and viewed traditional a
7                             In light of past commentaries, 4 papers also include reflections on the d
8                                      In this commentary, 4 areas of opportunity for epidemiology are
9                                 Twenty-seven commentaries add insights from diverse disciplines, such
10                                          The commentaries address our view of abstraction, our ontolo
11                                         This commentary addresses "mega-trends" that will affect the
12                                         This commentary addresses being an epidemiologist at a time w
13                       Therefore, the present commentary aimed to dive into the key advantages of the
14                                         This commentary aims to discuss the implications of reporting
15                                         Some commentaries also provide data relevant to CLASH.
16                           We suggest in this commentary an emotional origin of the Industrial Revolut
17  emerging infections, such as COVID-19, this commentary argues that all members of the health care te
18 ient reporting of experimental details, this commentary argues that the complexity of biological mate
19                                         This commentary article aims to identify priority EH practice
20                                         This commentary article identifies priority challenges and re
21                                      In this commentary, as members of both the SER and the Johns Hop
22                                         This commentary briefly surveys evidence showing that clear a
23  for this article.(C) RSNA, 2020See also the commentary by Alderson in this issue.
24 peutically using MTH1 inhibitors.See related commentary by Alnajjar and Sweasy, p.
25  strategies for antiangiogenesis.See related commentary by Amoozgar et al., p.
26 able for this article.(C) RSNA, 2020See also commentary by Andreisek in this issue.
27 their impact on patient survival.See related commentary by Anichini, p.
28 its bone marrow microenvironment.See related commentary by Boise and Shanmugam, p.
29 eregulation of the Hippo pathway.See related commentary by Brekken, p.
30 ly in African-American survivors.See related commentary by Brown and Richard, p.
31 ells in breast cancer metastasis.See related commentary by Bunz, p.
32 in regulating cancer progression.See related commentary by Calin, p.
33 o resensitize refractory disease.See related commentary by Canman, p.
34 tment of ovarian cancer patients.See related commentary by Carbone and Melino, p.
35 fit from multidrug immunotherapy.See related commentary by Carpenter et al., p.
36 ssion via its repression of POLQ.See related commentary by Carvajal-Maldonado and Wood, p.
37 2 as an ovarian cancer risk gene.See related commentary by Choi and Brown, p.
38 l is available for this article.See also the commentary by Choyke in this issue.
39 duce a robust antitumor response.See related commentary by Cordes and Metallo, p.
40 tate, Radiation Therapy(C) RSNA, 2020See the commentary by Davenport and Shankar in this issue.
41 creasing their metastatic spread.See related commentary by Davidson, p.
42 l is available for this article.See also the commentary by Elicker and Sohn in this issue.(C) RSNA, 2
43 tion of systemic IL6 in the host.See related commentary by Fiering and Ho, p.
44 osis or occlusion.(C) RSNA, 2020See also the commentary by Finn in this issue.
45 stance mechanisms are identified.See related commentary by Floros et al., p.
46 tential target in cancer therapy.See related commentary by Gan, p.
47                  (C) RSNA, 2020 See also the commentary by Gastounioti and Kontos in this issue.
48 G, while many tumor cells do not.See related commentary by Gius and Zhu, p.
49                   (C) RSNA, 2020See also the commentary by Grimm in this issue.
50 g response to therapy.(C) RSNA, 2020See also commentary by Gutberlet in this issue.
51 ensitivity to anti-PD-L1 therapy.See related commentary by Gutiontov and Weichselbaum, p.
52 or novel therapeutic development.See related commentary by Haines and Huang, p.
53  for this article.(C) RSNA, 2020See also the commentary by Halabi in this issue.
54 by radiosensitizing tumors cells.See related commentary by Hallahan, p.
55 nhibitor therapy for lung cancer.See related commentary by Havel, p.
56 ential target for cancer therapy.See related commentary by Horikawa, p.
57 y and promote antitumor immunity.See related commentary by Huang and Brekken, p.
58 ownstream testing.(C) RSNA, 2020See also the commentary by Ihdayhid and Ben Zekry in this issue.
59 or developing metastatic disease.See related commentary by Ingman, p.
60 ions of angiopoietin-2 in cancer.See related commentary by Kamiyama and Augustin, p.
61 ubset of patients.(C) RSNA, 2020See also the commentary by Kay and Abbara in this issue.
62                  (C) RSNA, 2020 See also the commentary by Kay in this issue.
63 l is available for this article.See also the commentary by Kay in this issue.(C) RSNA, 2020.
64 pressing markers of pluripotency.See related commentary by Koncar and Agnihotri, p.
65 geted therapy-induced senescence.See related commentary by Kondo, p.
66 1q as a novel therapeutic target.See related commentary by Korimerla and Wahl, p.
67 dict time to disease development.See related commentary by Kuijjer, p.
68 with and without prostate cancer.See related commentary by Lachance, p.
69                   (C) RSNA, 2020See also the commentary by Lakhani in this issue.
70 omising novel systemic therapies.See related commentary by Lambert and Jones, p.
71 ation and dependencies in cancer.See related commentary by Lathia, p.
72 ker of tumor response to therapy.See related commentary by Lee et al., p.
73                   (C) RSNA, 2020See also the commentary by Leiner in this issue.
74 get for therapeutic intervention.See related commentary by Man et al., p.
75                   (C) RSNA, 2020See also the commentary by Markl and Lee in this issue.
76 ow quantification.(C) RSNA, 2020See also the commentary by Markl in this issue.
77 teractome in EBV(+) malignancies.See related commentary by Mbulaiteye and Prokunina-Olsson, p.
78 lling tumor growth and migration.See related commentary by McAndrews and Kalluri, p.
79 nse prediction biomarkers in PDX.See related commentary by Meehan, p.
80 ses in adenomatous premalignancy.See related commentary by Merrick, p.
81 ogic modulation of transcription.See related commentary by Natarajan and Venneti, p.
82 ith immune checkpoint inhibitors.See related commentary by Nephew, p.
83 istory or genetic susceptibility.See related commentary by Niehoff et al., p.
84  turnaround times.(C) RSNA, 2021See also the commentary by O'Connor and Bhalla in this issue.
85 s and other monosomal karyotypes.See related commentary by O'Hagan et al., p.
86 with cell cycle and self-renewal.See related commentary by Pardini and Dragomir, p.
87  FDA-approved targeted therapies.See related commentary by Parrales and Iwakuma, p.
88  for this article.(C) RSNA, 2020See also the commentary by Peshock in this issue.
89 kpoint blockade as a monotherapy.See related commentary by Prokunina-Olsson, p.
90 tumor suppressor in osteosarcoma.See related commentary by Roberts, p.
91  associated with gene expression.See related commentary by Rodriguez-Antolin, p.
92 ytes and development of melanoma.See related commentary by Sahu, p.
93 mentation.(C) RSNA, 2020See also the invited commentary by Sala and Ursprung in this issue.
94 does sensitize to ATR inhibition.See related commentary by Setton and Powell, p.
95 re to alpha-particle irradiation.See related commentary by Sgouros, p.
96 r risk among healthy individuals.See related commentary by Song and Tworoger, p.
97 rks following Myc overexpression.See related commentary by Sotiriou and Halazonetis, p.
98                   (C) RSNA, 2020See also the commentary by Stillman in this issue.
99  management via adaptive therapy.See related commentary by Strobl et al., p.
100 apeutic strategies for treatment.See related commentary by Tan and Weljie, p.
101 l is available for this article.See also the commentary by Tenenholtz and Wood in this issue.(C) RSNA
102  2020Keywords: Breast, ScreeningSee also the commentary by Thigpen and Rapelyea in this issue.
103 ed questions in melanoma in vivo See related commentary by Thorkelsson et al., p.
104                   (C) RSNA, 2020See also the commentary by Tiwari and Verma in this issue.
105 vely infer different risk groups.See related commentary by Triche Jr, p.
106 te their tumor-killing potential.See related commentary by Tripodo, p.
107 c disease present.(C) RSNA, 2020See also the commentary by Truong and Villines in this issue.
108  responsive to kinase inhibitors.See related commentary by Valeri, p.
109 m may have therapeutic relevance.See related commentary by Wang and Wulf, p.
110 f PRMT function in tumorigenesis.See related commentary by Watson and Bitler, p.
111                   (C) RSNA, 2020See also the commentary by Weiss and Solomon in this issue.
112                  (C) RSNA, 2020 See also the commentary by White and Rubin in this issue.
113 considerations for immunotherapy.See related commentary by Wisdom and Kirsch p.
114  for this article.(C) RSNA, 2020See also the commentary by Yousefi.
115  between normal and tumor tissue.See related commentary by Zoete and Coukos, p.
116 py for patients with lung cancer.See related commentary by Zou and Meyerson, p.
117 s before radiographic assessment.See related commentary by Zou and Meyerson, p.
118                                      In this commentary, by way of example in health disparities rese
119                          The authors of this commentary call for sex- and gender-specific and differe
120                                         This commentary complements it by considering how attacker-de
121                                         This commentary complements the article by De Dreu and Gross
122  broader theoretical issues arising from the commentaries, concerning in particular the question as t
123                                         This commentary considers an extreme idea for protecting agai
124                                         This commentary construes the relation between the two system
125 s of terrorism in political discourse, media commentary, contemporary culture, and academic inquiry.
126                                         This commentary covers current issues and challenges for the
127                                         This commentary defends an alternative interpretation of this
128                                         This commentary describes the risks of the collision of the C
129                                         This commentary describes the use and benefits of implementat
130                                         This commentary discuss why pregnancy women should be include
131                                         This Commentary discusses how a parallel effort to address fu
132                                         This commentary discusses how to balance a delay in cancer di
133                                         This commentary discusses new applications of CRISPR-based ge
134                                         This commentary discusses the advantages of 3-dimensional his
135                                         This commentary discusses the COVID-19 pandemic on the Africa
136                                         This commentary discusses the early licensing and deployment
137                                         This commentary discusses the findings of early studies that
138                                         This commentary discusses the importance of environmental cle
139                                         This commentary discusses the value of residents during the c
140                                         This commentary draws connections between technological cultu
141                                           My commentary draws on extensive arguments against "coding
142                                         This commentary drills down on a core theme in their argument
143    Studies without full reports or abstract, commentaries, editorials, and reviews were excluded.
144                                         This commentary evaluates two possible options to justify the
145                                         This commentary examines the historical arc of the 1918 influ
146                                          Our commentary expands this framework to accommodate multipl
147                                         This commentary explores historical examples of population-wi
148                                         This commentary explores how emotion fits in the dual-systems
149                                         This commentary explores modifications to the carbapenem inac
150                                         This commentary extends the target article's useful concepts
151                           My response to the commentaries focuses on four issues: (1) the diversity b
152                                         This commentary focuses upon the relationship between two the
153 rateful to have received so many stimulating commentaries from interested colleagues regarding the ps
154                                Responding to commentaries from psychologists, neuroscientists, philos
155                                          The commentaries have both revealed the implications of and
156                                         This commentary highlights an extraordinary international col
157                                         This commentary highlights the article by Bernard et al that
158                                         This commentary highlights the article by Clerbaux et al that
159                                         This commentary highlights the article by Dakin et al that de
160                                         This commentary highlights the article by Fang et al that des
161                                         This commentary highlights the article by Francipane et al th
162                                         This commentary highlights the article by Hara et al that dis
163                                         This commentary highlights the article by Hathaway-Schrader e
164                                         This commentary highlights the article by Jin et al that stud
165                                         This commentary highlights the article by Li et al that ident
166                                         This commentary highlights the article by Li et al that links
167                                         This commentary highlights the article by Ruggeri et al that
168                                         This commentary highlights the unique and complementary roles
169                                      In this commentary I suggest a way in which another paradox of o
170                                      In this commentary, I criticize their teleocentric view as being
171                                      In this commentary, I describe how this process is consistent wi
172                                      In this commentary, I describe my experience with CoV disease 20
173                                      In this commentary, I draw attention to welfare state theory and
174                                      In this commentary, I draw attention to welfare-state theory and
175                                      In this commentary, I highlight the relevance of Cushman's targe
176                                    Since our commentary in 2017, there have been many more studies su
177 depicting general neutral or positive social commentaries) internet memes.
178                                         This commentary introduces a new clinical trial construct, th
179                                         This commentary is a reflection of the authors' experience on
180                                              Commentary is given on the entire process of writing ori
181                        The objective of this commentary is to articulate a conceptual framework incor
182                              The aim of this commentary is to discuss the advantages and disadvantage
183                        Our objective in this commentary is to discuss the strengths, limitations, and
184                        The objective of this commentary is to emphasize that you can't drive a car wi
185                          A key focus of this commentary is to offer an alternative perspective on bot
186                          A key focus of this commentary is to offer an alternative perspective on bot
187                          The purpose of this commentary is to provide an overview of the methods used
188                        The objective of this commentary is to underscore the importance of diversity
189                                         This commentary links the climate crisis with the pandemic in
190                                         This commentary makes three points: (1) the existing evidence
191                                      In this commentary, methodological challenges and opportunities
192                                         This commentary offers suggestions to encourage a culture tha
193                               We address the commentaries on our target article in terms of four majo
194  three main sets of topics emerging from the commentaries on our target article.
195                                      In this commentary on Bastin et al., we suggest that spatial con
196                                      In this commentary on Borsboom et al.'s target article, I addres
197                                      In this commentary on Borsboom et al.'s target article, we argue
198                                    This is a commentary on Brookshire et al. 26, 5404-5413 For the No
199 lled release therapeutics is appraised, with commentary on current success/failures in systemic carri
200                            This article is a commentary on DeLeo et al, 26, 523-538.
201 five quality of evidence statements, and one commentary on disclosure was developed.
202                            This article is a commentary on Hapsari et al. 26, 1414-1431.
203       Summary statistics are provided with a commentary on implications for practices and treatment o
204                                         This commentary on Jussim's 2012 book analyzes these developm
205                            This article is a commentary on Kennedy et al., 25, 811-826; See also the
206                            This article is a commentary on Kennedy et al., 25, 811-826; See also the
207                            This article is a Commentary on Lui et al. (2020), 228: 269-284.
208                            This article is a Commentary on Mark et al. (2020), 227: 1362-1375.
209                                      In this commentary on May's Regard for Reason in the Moral Mind,
210                                      In this commentary on Osiurak and Reynaud's target article, we a
211                            This article is a commentary on Slette et al., 25, 3193-3200; See also the
212 se-responsive delivery systems, and provides commentary on the opportunities and barriers ahead regar
213                     Additionally, we provide commentary on the opportunities and challenges ahead in
214 n both sides of this controversy, to provide commentary on the purported requirement of MELK in cance
215 on Kennedy et al., 25, 811-826; See also the Commentary on this article by Kennedy et al., 26, 333-33
216 on Kennedy et al., 25, 811-826; See also the Commentary on this article by Venter et al., 26, 330-332
217                             There is a Blood Commentary on this article in this issue.
218           Publisher's Note: There is a Blood Commentary on this article in this issue.
219                 See Basbaum for a scientific commentary on this article.
220                  See Schiff for a scientific commentary on this article.
221 ravaggio and Graff-Guerrero for a scientific commentary on this article.Antipsychotic drugs, original
222         See Saporta and Shy for a scientific commentary on this article.Effective bidirectional signa
223        See Vidailhet et al. for a scientific commentary on this article.Misdiagnosis among tremor syn
224                 See Hamandi for a scientific commentary on this article.Photosensitivity is a conditi
225  SUN ET AL DOI101093/AWW306 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: About 20% of patients with i
226                            This article is a Commentary on Wagner et al.
227 focused solely on contrast agents, served as commentaries/overviews on NIRAF or were not written in E
228                                         This commentary presents how controlled vocabularies, thesaur
229                                         This commentary proposes a definition for the term "peri-impl
230                          The authors of this commentary provide guidance for clinical decision making
231                                        These commentaries provided us with an opportunity to clarify
232                                         This commentary provides an overview of Rothman's "sufficient
233                                         This commentary provides clinicians with guidance on how to a
234                   We included editorials and commentaries published in American Journal of Epidemiolo
235                                          The commentaries raised questions about normativity, human r
236                                         This commentary raises a question about the target article's
237                                          The commentary raises problems for both of these options.
238                                         This commentary raises two interrelated theoretical concerns
239                              This scientific commentary refers to 'Aberrant interaction between FUS a
240                              This scientific commentary refers to 'Brain-first versus body-first Park
241                              This scientific commentary refers to 'Brainstem spreading depolarization
242                              This scientific commentary refers to 'Diabetes medications and risk of P
243                              This scientific commentary refers to 'Evolution of prodromal Parkinson's
244                              This scientific commentary refers to 'Gene replacement ameliorates defic
245                              This scientific commentary refers to 'Global CNS correction in a large b
246                              This scientific commentary refers to 'Identification of neurotoxic cross
247                              This scientific commentary refers to 'Impaired forward model updating in
248                              This scientific commentary refers to 'Local sleep-like cortical reactivi
249                              This scientific commentary refers to 'Longitudinal multimodal MRI as pro
250                              This scientific commentary refers to 'Network localization of clinical,
251                              This scientific commentary refers to 'NLRP3 inflammasome as prognostic f
252                              This scientific commentary refers to 'Nogo receptor decoy promotes recov
253                              This scientific commentary refers to 'O-GlcNAcylation regulates dopamine
254                              This scientific commentary refers to 'Particulate matter and episodic me
255                              This scientific commentary refers to 'Persistent neuropathological effec
256                              This scientific commentary refers to 'Polygenic risk score increases sch
257                              This scientific commentary refers to 'Risk and predictors of dementia an
258                              This scientific commentary refers to 'Slow blood-to-brain transport unde
259                              This scientific commentary refers to 'Spatiotemporal changes in substant
260                              This scientific commentary refers to 'Virtual resection predicts surgica
261                              This scientific commentary refers to 'When affect overlaps with concept:
262                                         This commentary relates Hoerl & McCormack's dual systems pers
263 istory of our moral stance told here in this commentary reveals the close nexus of morality and basic
264                                         This Commentary seeks to describe the burgeoning field of "ca
265                                         This commentary specifically addresses best ways to protect o
266                                          The commentaries suggest many important improvements to the
267                                         Many commentaries suggest that incentive hope even could help
268                                         This commentary summarizes the publication history of Global
269 sented, and I wholeheartedly agree with many commentaries that more work is needed.
270                                      In this commentary, the author addresses several areas of curren
271                                      In this commentary, the authors discuss multiple potential clini
272                                      In this commentary, the authors explain and call for a broader u
273                               In the present commentary, the authors' viewpoint is discussed in light
274                                      In this commentary, the processes within these subsystems are qu
275                                         This commentary uses the dynamic of identity-protective cogni
276                                  This expert commentary was commissioned and approved by the AGA Inst
277                           In response to the commentaries, we have refined our suggested model and di
278                                      In this commentary, we ask when rationalization is most likely t
279                                      In this commentary, we assert that the inclusion of political le
280                                      In this commentary, we describe how this might be explained by a
281                                      In this commentary, we describe validity issues underlying these
282                                      In this commentary, we discuss how choice of conference location
283                                      In this commentary, we discuss how the "incentive hope" hypothes
284                                      In this commentary, we discuss the importance and limits of pati
285                                      In this commentary, we discuss the inconsistency of the interact
286                                      In this commentary, we discuss the meaning of the "individual ef
287                                      In this commentary, we highlight a crucial challenge posed by th
288                                      In this commentary, we highlight recent progress in this burgeon
289                                      In this commentary, we highlight some of the latest studies that
290                                      In this commentary, we justify the need to study more diverse po
291                                      In this commentary, we offer an additional function of rationali
292                                      In this commentary, we propose 2 key contributions that systems
293                              In this invited commentary, we propose that Blackburn (XXXX) ignores sev
294                                      In this commentary, we provide a broad overview of how the rapid
295                                In this brief commentary, we provide an analysis of the conceptual and
296                                      In this commentary, we put these findings in the broader context
297                                      In this commentary, we review the timeline of clinical trials an
298                                      In this commentary, we suggest a skeleton framework upon which d
299                                         This commentary will describe the background, organization, f
300                                         This commentary will help answer those questions as it guides

 
Page Top